Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alchemab Therapeutics
Biotech
Eli Lilly licenses ALS drug program from Alchemab in $415M pact
Four months after Eli Lilly and British biotech Alchemab penned a discovery collab, the Big Pharma is licensing its first drug asset from the deal.
Ben Adams
May 6, 2025 8:54am
Lilly crafts deal with UK biotech for new ALS antibodies
Jan 9, 2025 10:55am
Cue Biopharma queues up J&J vet as CBO—Chutes & Ladders
Sep 13, 2024 8:30am
Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders
May 27, 2022 9:30am
Lightstone raises $375M for third fund after 3 big exits in 2020
Sep 14, 2021 10:05am
Alchemab picks up new well-connected CEO
Jun 22, 2021 10:25am
